Integrated BioPharma Inc (INBP)
OTHER OTC:INBP
Want to see INBP full AI Analyst Report?
Top Page
Integrated BioPharma
(OTC:INBP)
Select Model
Select Model
Rating:54Neutral
Price Target:
$0.25
▼(-27.94% Downside)
Action:ReiteratedDate:04/16/26
The score is held back primarily by deteriorating operating performance (sharp TTM revenue decline and a return to net losses) and weak technical trend signals (below major moving averages with negative MACD). These are partially offset by low leverage and positive free cash flow, with a modest boost from the credit facility extension easing near-term liquidity pressure.
Positive Factors
Low leverage balance sheet
A very low debt load and conservative balance sheet provide durable financial flexibility. With minimal interest obligations the company can absorb revenue volatility, maintain operations through downturns, and has optionality to fund working capital, capex or opportunistic M&A without immediate refinancing pressure.
Negative Factors
Sharp revenue decline & return to loss
A steep TTM revenue drop and a swing to net loss materially reduce operational scale and margin absorption. Persisting top-line weakness makes fixed costs harder to cover, limits reinvestment capacity, and raises execution risk for any turnaround given the dependence on sustaining contract volumes or distribution sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage balance sheet
A very low debt load and conservative balance sheet provide durable financial flexibility. With minimal interest obligations the company can absorb revenue volatility, maintain operations through downturns, and has optionality to fund working capital, capex or opportunistic M&A without immediate refinancing pressure.
Read all positive factors
Integrated BioPharma (INBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.84M
Dividend YieldN/A
Average Volume (3M)15.15K
Price to Earnings (P/E)―
Beta (1Y)-0.10
Revenue Growth-0.06%
EPS Growth-120.13%
CountryUS
Employees147
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.01
Shares Outstanding31,059,610
10 Day Avg. Volume31,065
30 Day Avg. Volume15,153
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.53
Price to Sales (P/S)0.20
P/FCF Ratio5.77
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue0.06
Enterprise Value/Gross Profit0.76
Enterprise Value/Ebitda1.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Integrated BioPharma Business Overview & Revenue Model
Company Description
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract M...
How the Company Makes Money
Integrated BioPharma primarily makes money in two ways: (1) contract manufacturing revenue and (2) distribution/wholesale revenue. On the manufacturing side, the company earns fees by producing dietary/nutritional supplement products for third-par...
Integrated BioPharma Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
64
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.09M | 54.35M | 50.32M | 50.67M | 56.25M | 63.56M |
| Gross Profit | 4.07M | 5.56M | 3.88M | 4.06M | 6.55M | 9.48M |
| EBITDA | 1.83M | 3.38M | 1.47M | 1.27M | 3.56M | 6.61M |
| Net Income | -206.00K | 808.00K | 112.00K | -34.00K | 3.84M | 8.01M |
Balance Sheet | ||||||
| Total Assets | 23.55M | 24.90M | 26.21M | 25.43M | 25.25M | 25.44M |
| Cash, Cash Equivalents and Short-Term Investments | 5.31M | 3.62M | 1.68M | 1.32M | 331.00K | 210.00K |
| Total Debt | 649.00K | 1.01M | 1.80M | 2.67M | 2.06M | 4.33M |
| Total Liabilities | 3.78M | 4.58M | 6.97M | 6.57M | 6.67M | 11.11M |
| Stockholders Equity | 19.77M | 20.32M | 19.24M | 18.86M | 18.57M | 14.33M |
Cash Flow | ||||||
| Free Cash Flow | 2.81M | 1.87M | 390.00K | 1.12M | 3.60M | 2.75M |
| Operating Cash Flow | 3.13M | 2.06M | 943.00K | 1.23M | 4.09M | 3.05M |
| Investing Cash Flow | -317.00K | -205.00K | -553.00K | -111.00K | -465.00K | -199.00K |
| Financing Cash Flow | 45.00K | 78.00K | -29.00K | -136.00K | -3.50M | -3.04M |
Integrated BioPharma Technical Analysis
Negative
0.34
Price Trends
0.29
Negative
0.31
Negative
0.30
Negative
Market Momentum
>-0.01
Negative
42.82
Neutral
43.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBP, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.29, and above the 200-day MA of 0.30, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 42.82 is Neutral, neither overbought nor oversold. The STOCH value of 43.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBP.
Integrated BioPharma Risk Analysis
Integrated BioPharma disclosed 20 risk factors in its most recent earnings report. Integrated BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Integrated BioPharma Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | $90.62M | 23.18 | 15.30% | ― | 26.35% | -30.60% | |
54 Neutral | $7.84M | -3.62 | -1.02% | ― | -0.06% | -120.13% | |
46 Neutral | $16.49M | -2.11 | -17.43% | ― | 10.24% | -55.68% | |
46 Neutral | $10.16M | -0.62 | -3.59% | ― | -21.70% | -109.55% | |
46 Neutral | $6.11M | -0.63 | -74.59% | ― | ― | ― | |
40 Underperform | $35.29M | -0.04 | -214.22% | ― | -81.88% | -672.07% |
* Consumer Defensive Sector Average
INBP
Integrated BioPharma
0.25
-0.02
-6.67%
NAII
Natural Alternatives International
2.67
-0.03
-1.11%
SOWG
Sow Good
1.76
-7.61
-81.22%
FTLF
FitLife Brands
9.65
-5.91
-37.98%
BON
Bon Natural Life
1.25
-0.16
-11.42%
HCWC
Healthy Choice Wellness Corp. Class A
0.27
-0.13
-33.00%
Integrated BioPharma Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Integrated BioPharma Extends Credit Facility, Eases Liquidity Pressure
Positive
Apr 15, 2026
On April 14, 2026, Integrated BioPharma, Inc. and its wholly owned subsidiary Manhattan Drug Company, Inc. received notice from PNC Bank that the expiration date of their existing line of credit, originally set for April 15, 2026 under a 2025 prom...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.